Cyclacel Pharma (CYCC) Misses Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Join SI Premium – FREE
Cyclacel Pharma (NASDAQ: CYCC) reported Q2 EPS of ($0.16), $0.04 worse than the analyst estimate of ($0.12).
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
- UBS Reiterates Buy Rating on Darden Restaurants (DRI) Ahead of Q1 Earnings
- Macy's (M) Stock: Street Underestimates Earnings Pressure From Share Loss, Says Analyst
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
